Trastuzumab Deruxtecan in Previously Treated HER2 …
2020年5月29日 · Here, we share the results of an open-label, multicenter, phase 2 trial of trastuzumab deruxtecan in patients with HER2-expressing advanced …
- 作者: Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheo...
- Publish Year: 2020
HER-2 positive gastric cancer: Current targeted treatments
2024年8月1日 · Emerging targeted therapies for HER2 positive gastric cancer that can overcome trastuzumab resistance
HER2-targeted therapies in gastric cancer - PubMed
In this study, we will summarize the recent advances in anti-HER-2 agents, potential mechanisms of resistance to HER2-targeted therapy in HER2-positive gastric cancer. We will also discuss …
- 作者: Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
- Publish Year: 2021
- Her2 ADC Gastric Cancer 的研究
Development of Treatment Strategies for Advanced HER2-positive …
HER2-positive gastric cancer (GC), a unique molecular subtype, has garnered significant interest in recent years. Here, we review clinical trial data on advanced HER2-positive GC from the …
Targeted therapy and immunotherapy for gastric cancer: rational ...
2025年2月8日 · Gastric cancer (GC) is one of the most common malignant tumors worldwide, and its treatment has been a focus of medical research. ... (ADC) targeting HER2 have been …
HER2-targeted therapies in gastric cancer - ScienceDirect
2021年8月1日 · Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: a multi-institutional phase Ib/II trial of first-line …
- 其他用户还问了以下问题
HER2-Positive Gastric Cancer and Antibody Treatment: …
2024年3月29日 · The antibody–drug conjugate (ADC) trastuzumab-deruxtecan (Enhertu, T-DXd) is the first new therapeutic agent targeting HER2 to enter standard therapy for metastatic HER2-positive gastric cancer since the …
Disitamab vedotin (RC48) plus toripalimab for HER2 …
2023年8月8日 · Although the antibody–drug conjugates (ADCs) have significantly improved the survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, the …
A literature review of recent advances in gastric cancer treatment ...
An ADC consisting of a cytotoxic topoisomerase I inhibitor, a linker, and an anti-HER2 antibody, called trastuzumab deruxtecan (DS-8201), is known as a HER2-targeted ADC. Shitara et al. …
Efficacy and safety of different drugs in patients with HER2 …
6 天之前 · Background In the past decade, there has been a significant advancement in targeted therapy and immunotherapy, leading to the discovery of new drugs and changes in the …
